Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Wins NY State Approval for NGS Pre-Implantation Genetic Screening

NEW YORK (GenomeWeb) – CombiMatrix said today that that the New York State Department of Health has approved its next-generation sequencing pre-implantation genetic screening test.

The company's CombiPGS test screens embryo biopsy cells for chromosomal abnormalities prior to implantation in women undergoing in vitro fertilization.

CombiMatrix introduced the new NGS version of the test this June, with the goal of transitioning all customers of its previous array-based PGS test to the newer sequencing version.

"CombiPGS by NGS is an important upgrade to our portfolio of reproductive health tests and we are pleased by the strong reception it has received from reproductive endocrinologist and IVF physicians who are key call points for this test," CombiMatrix President and CEO Mark McDonough said in a statement.

With this new approval, the company can now market the NGS version of the test in New York State, which McDonough said ranks second in the total number of IVF cycles performed nationally each year.